Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01437
|
|||||
| Drug Name |
UCN-01
|
|||||
| Synonyms |
UCN; UCN01; Ucn 01; KRX-0601; KW-2401; UCN-02; (5s,6r,7r,9r,16r)-16-hydroxy-6-methoxy-5-methyl-7-(methylamino)-6,7,8,9,15,16-hexahydro-5h,14h-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-14-one; 7-Hydroxystaurosporine; 7-hydroxystaurosporine (UCN-01)
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Non-small cell lung cancer [ICD11: 2C25] | Phase 2 | [1] | |||
| Therapeutic Class |
Anticancer Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C28H26N4O4
|
|||||
| Canonical SMILES |
CC12C(C(CC(O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)C(NC6=O)O)NC)OC
|
|||||
| InChI |
InChI=1S/C28H26N4O4/c1-28-25(35-3)15(29-2)12-18(36-28)31-16-10-6-4-8-13(16)19-21-22(27(34)30-26(21)33)20-14-9-5-7-11-17(14)32(28)24(20)23(19)31/h4-11,15,18,25,27,29,34H,12H2,1-3H3,(H,30,33)/t15-,18-,25-,27-,28+/m1/s1
|
|||||
| InChIKey |
PBCZSGKMGDDXIJ-HQCWYSJUSA-N
|
|||||
| CAS Number |
CAS 112953-11-4
|
|||||
| Pharmaceutical Properties | Molecular Weight | 482.5 | Topological Polar Surface Area | 89.7 | ||
| Heavy Atom Count | 36 | Rotatable Bond Count | 2 | |||
| Hydrogen Bond Donor Count | 3 | Hydrogen Bond Acceptor Count | 5 | |||
| XLogP |
2.7
|
|||||
| PubChem CID | ||||||
| PubChem SID |
499504
, 597067
, 828000
, 828774
, 829609
, 7890973
, 7980340
, 11417349
, 12014075
, 14834856
, 14859145
, 43128463
, 46392797
, 46517284
, 49965093
, 53789227
, 57318623
, 75855760
, 93575990
, 103073266
, 103083413
, 104252674
, 117623524
, 131269002
, 134338729
, 135030252
, 139892065
, 143298032
, 163685599
, 198960442
, 227749464
, 247172087
, 249565590
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
| References | ||||||
| 1 | ClinicalTrials.gov (NCT00098956) 7-hydroxystaurosporine and Topotecan Hydrochloride in Treating Patients With Relapsed or Progressed Small Cell Lung Cancer | |||||
| 2 | Pharmacogenomic importance of ABCG2. Pharmacogenomics. 2008 Aug;9(8):1005-9. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.